Qu Biologics Revenue and Competitors

Burnaby,

Location

#6493

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • Qu Biologics's estimated annual revenue is currently $2.2M per year.(i)
  • Qu Biologics's estimated revenue per employee is $77,500
  • Qu Biologics's total funding is $30M.

Employee Data

  • Qu Biologics has 28 Employees.(i)
  • Qu Biologics grew their employee count by 17% last year.

Qu Biologics's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Qu Biologics?

Qu Biologics is a Vancouver-based, private, clinical stage biotechnology company developing Site Specific Immunomodulators (SSI), a novel proprietary immunotherapy platform. SSIs are designed to stimulate an innate immune response in targeted organs or tissues to reverse the chronic inflammation underlying many diseases including cancer and inflammatory bowel disease (Crohn's disease, ulcerative colitis). SSIs aim to restore immune function and have potential broad applicability across a wide variety chronic diseases. The company has initiated three clinical trials in Crohn's disease, ulcerative colitis and lung cancer. Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and CEO Dr. Hal Gunn, a physician and expert on the body's immune response to chronic disease and Chief Medical Officer Dr. Simon Sutcliffe, former CEO of the BC Cancer Agency and a distinguished clinician, scientist and leader in cancer control internationally. We are always interested in talented biotechnology professionals and know that some of the best team members can be found when you're not looking for them. For Qu, finding the right team member is not about matching a resume to a checklist of skills, it's about integrity and character. If you have big ideas, love a fast-paced innovative environment and you're up for the challenge, we want to hear from you. Send us your resume and a detailed cover letter telling us about yourself and how you feel you could contribute. Applications can be sent, in confidence, to jobs@qubiologics.com.

keywords:N/A

$30M

Total Funding

28

Number of Employees

$2.2M

Revenue (est)

17%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Qu Biologics News

2022-03-22 - Qu Biologics Closes USD$12M Equity Financing

Backed by a prestigious group of scientific advisors and board members, Qu Biologics is led by a management team that includes co-founder and...

2021-06-23 - Qu Biologics Receives Additional Funding to Accelerate Clinical Development of Qu's First-in-Class Immunotherapeutic for COVID-19 Prevention and Treatment

VANCOUVER, British Columbia, June 23, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce it is rece ...

2020-12-09 - Qu Biologics Completes $8M Financing

VANCOUVER, British Columbia, Dec. 09, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a private clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce an oversub ...

2020-08-24 - Qu Biologics is pleased to announce the appointment of Karn Manhas to Qu's Board of Directors

VANCOUVER, British Columbia, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of immunotherapies designed to restore innate immune function, is pleased to announce that Karn Manhas, Founder and CEO ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2.5M313%N/A
#2
N/A3343%N/A
#3
$2.8M35-12%N/A
#4
$9.9M350%N/A
#5
$8.1M350%N/A